aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Kymera Therapeutics, founded with the mission to revolutionize medicine through targeted protein degradation, focuses on developing innovative drugs to treat previously untreatable acute and chronic diseases. The company leverages a disease-agnostic modality that fundamentally changes how drugs can work, thereby expanding the range of treatable diseases. Kymera aims to address critical health problems and significantly improve patients' lives by targeting the fundamental drivers of disease.
Notable figures associated with Kymera Therapeutics include leading scientists and industry experts who have driven the company's pioneering research. The firm has attracted significant investment from prominent venture capital firms, underscoring its potential and credibility in the biopharmaceutical sector. Key achievements include advancing multiple drug candidates into clinical trials, demonstrating the practical application of their targeted protein degradation technology. Kymera's innovative approach has positioned it as a transformative player in the global healthcare landscape.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Drugs
Technology
Biotech
Tags
Biotech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Kymera Therapeutics founded?
Kymera Therapeutics was founded in 2017.
Where is Kymera Therapeutics’s headquarters located?
Kymera Therapeutics’s headquarters is located in Cambridge, MA, US.
When was Kymera Therapeutics’s last funding round?
Kymera Therapeutics’s most recent funding round was for $275M (USD) in January 2024.
How many employees does Kymera Therapeutics have?
Kymera Therapeutics has 167 employees as of Feb 6, 2024.
How much has Kymera Therapeutics raised to-date?
As of July 05, 2023, Kymera Therapeutics has raised a total of $879M (USD) since Jan 5, 2024.
Add Comparison
Total Raised to Date
$879M
USD
Last Update Jan 5, 2024
Last Deal Details
$275M
USD
Jan 5, 2024
Post Ipo Equity
Total Employees Over Time
167
As of Feb 2024
Kymera Therapeutics Address
400 Technology Square
10th Floor
Cambridge,
Massachusetts
02139
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts